In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines-Reference-Cited by-同舟云学术

In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines

Published:2002-11 Issue:11 Volume:13 Page:1743-1748
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Merlin J.-L.,Barberi-Heyob M.,Bachmann N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/13/11/1743/531945/mdf263.pdf

Reference34 articles.

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene;Coussens;Science,1985

2. Clinical significance of HER2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group;Seshadri;J Clin Oncol,1993

3. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene;Slamon;Science,1987

4. Tissue microarrays for gene amplification surveys in many different tumor types;Schraml;Clin Cancer Res,1999

5. Her-2/neu overexpression in pancreatic adenocarcinoma;Safran;Proc Am Soc Clin Oncol,2000

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RGS10 deficiency facilitates distant metastasis by inducing epithelial-mesenchymal transition in breast cancer;ELIFE;2024

2. RGS10 deficiency facilitates distant metastasis by inducing epithelial–mesenchymal transition in breast cancer;eLife;2024-08-15

3. RGS10 deficiency facilitates distant metastasis by inducing epithelial–mesenchymal transition in breast cancer;eLife;2024-08-15

4. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload;Bioorganic Chemistry;2024-08

5. Failure to progress: breast and prostate cancer cell lines in developing targeted therapies;Cancer and Metastasis Reviews;2024-07-26